Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Methylation of lysine residues on histone tail is a dynamic epigenetic modification that plays a key role in chromatin structure and gene regulation. Members of the KDM5 (also known as JARID1) sub-family are 2-oxoglutarate (2-OG) and Fe2+-dependent oxygenases acting as histone 3 lysine 4 trimethyl (H3K4me3) demethylases, regulating proliferation, stem cell self-renewal, and differentiation. Here we present the characterization of KDOAM-25, an inhibitor of KDM5 enzymes. KDOAM-25 shows biochemical half maximal inhibitory concentration values of <100 nM for KDM5A-D in vitro, high selectivity toward other 2-OG oxygenases sub-families, and no off-target activity on a panel of 55 receptors and enzymes. In human cell assay systems, KDOAM-25 has a half maximal effective concentration of ∼50 μM and good selectivity toward other demethylases. KDM5B is overexpressed in multiple myeloma and negatively correlated with the overall survival. Multiple myeloma MM1S cells treated with KDOAM-25 show increased global H3K4 methylation at transcriptional start sites and impaired proliferation.

Original publication




Journal article


Cell Chem Biol

Publication Date





371 - 380


2-oxoglutarate oxygenases, JARID1B, KDM5B, chromatin, demethylases, epigenetics, histones, lysine demethylation, myeloma, oncology, Cell Cycle Checkpoints, Cell Line, Tumor, Cell Proliferation, Cell Survival, Crystallography, X-Ray, Glycine, HeLa Cells, Histones, Humans, Kaplan-Meier Estimate, Ketoglutaric Acids, Methylation, Multiple Myeloma, Niacinamide, Protein Isoforms, Pyridines, Retinoblastoma-Binding Protein 2, Transcription Initiation Site